Laurion Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Laurion Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,200	Closed	-$5.85M	–	558
2022 Q3	$5.85M	Buy	+20,200	New	+$5.81M	0.03%	238
2019 Q4	–	Sell	-20,000	Closed	-$3.39M	–	1265
2019 Q3	$3.39M	Buy	+20,000	New	+$3.54M	0.03%	411
2018 Q4	–	Sell	-6,600	Closed	-$1.27M	–	1447
2018 Q3	$1.27M	Buy	+6,600	New	+$1.18M	0.01%	626

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Laurion Capital Management's VRTX Position: Q2 2026 in Review

Laurion Capital Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 4,706 shares worth $2.34M. The stake represents 0.06% of the portfolio and ranks #204 among its holdings. This is a return to the name: Laurion Capital Management previously reported a position in VRTX as recently as Q4 2025.

Laurion Capital Management first reported a position in VRTX in Q2 2015 and has held it in 12 quarters since. The position peaked at $28.3M in Q1 2017. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Laurion Capital Management held 4,706 shares of Vertex Pharmaceuticals worth $2.34M as of Q2 2026.
Vertex Pharmaceuticals was a new Laurion Capital Management position in Q2 2026.
Vertex Pharmaceuticals made up 0.06% of Laurion Capital Management's portfolio in Q2 2026, its #204 holding.
Laurion Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 12 quarters since.
Laurion Capital Management's Vertex Pharmaceuticals position peaked at $28.3M in Q1 2017.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.